Alex Biese

CURE sat down with Dr. Kathie-Ann Joseph to discuss surgical advancements for individuals with breast cancer.

Oral KTX-1001 achieved 40% disease control in phase 1 trials, offering a new targeted therapy for aggressive t(4;14) translocation multiple myeloma.

Smoldering multiple myeloma is a complex, intermediary stage of plasma cell disorders that requires a nuanced approach to care.

Dr. Anne Peled, a two-time breast cancer survivor, underwent a sensation-preserving mastectomy, a procedure she co-developed.

The FDA approved Darzalex Faspro with Velcade, Revlimid and dexamethasone for newly diagnosed multiple myeloma ineligible for autologous stem cell transplant.

Among patients with advanced breast cancer, levels of circulating tumor DNA before treatment may predict their response to targeted therapy.

Researchers sought to address a critical gap in the health care system where 85% of U.S. children diagnosed with cancer survive at least five years.

Receiving a diagnosis of squamous cell carcinoma can be an overwhelming experience, but it is important to remember that you are not alone.

The FDA approved Guardant360 CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer who may benefit from Braftovi with Erbitux and chemotherapy.

MammaPrint and BluePrint tests may help identify HR+/HER2– early-stage breast cancer patients likely to benefit from anthracycline-based chemotherapy.

The FDA accepted a new drug application for gedatolisib for patients with HR+, HER2-, PIK3CA wild-type advanced breast cancer.

In patients with high-risk melanoma, intismeran autogene and Keytruda reduced the risk of recurrence or death compared to Keytruda alone.

Patients with relapsed/refractory diffuse large B-cell lymphoma who received Epkinly alone experienced an improvement in progression-free survival.

This guide is designed to provide you with a clear medical foundation so you can engage in informed, collaborative discussions with your oncology team.

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination and what its approval by the FDA would mean for patients.

In patients with relapsed/refractory multiple myeloma, Tecvayli monotherapy is associated with a 71% reduction in the risk of disease progression or death.

CURE sat down with Dr. E. Antonio Chiocca to discuss a new brain cancer treatment being studied in an ongoing clinical trial.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

Bill Potts, a five-time cancer survivor, likes to refer to himself as “the luckiest guy I know.”

After Donna Rigby visited the emergency department at Hackensack Meridian Jersey Shore University Medical Center, tests showed stage 2 lung cancer.

Understanding your diagnosis, the tests ahead and the treatment landscape is the first step in regaining a sense of control.

These were the top gastrointestinal cancer stories published by CURE in 2025.

Dr. Erika Hamilton sat down for an interview with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration.

The NCCN hosted a Patient Advocacy Summit to address elevated cancer risks and specific healthcare needs of veterans and first responders.

Education is a vital step in navigating gallbladder cancer care.

Subgroup analysis of the phase 3 FOCUS study of patients with uveal melanoma has been announced.

CURE spoke with Dr. Natalie S. Berger for the latest episode of the "Cancer Horizons" podcast.

CURE spoke with an expert about smoking-related stigmas often faced by patients with lung cancer.

“Full House” star Dave Coulier, now undergoing treatment for tongue cancer, sat down for an interview with CURE.